Study on the efficacy of Xuanfeizhisou Mixture in the treatment of COVID-19 cough
- Conditions
- COVID-19
- Registration Number
- ITMCTR2200006141
- Lead Sponsor
- Shuguang Hospital Affiliated to Shanghai University of T.C.M.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients with mild and moderate novel coronavirus pneumonia confirmed in accordance with the Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9th); (2) TCM syndrome differentiation is wind evil and lung syndrome; (3) Two points for cough symptoms score; (4) Age is over 18-75 years old, with no limit on gender.
(1) Patients with severe pneumonia requiring mechanical ventilation and critical novel coronavirus pneumonia; (2) Those who are expected to die within 48 hours; (3) Respiratory tract infections caused by primary immune deficiency disease, acquired immune deficiency syndrome, congenital respiratory malformations, congenital heart disease, lung development abnormalities and other basic diseases; (4) Chest CT confirmed the existence of serious lung interstitial lesions and other underlying lung diseases; (5) According by the researchers, previous or current diseases may affect the outcome of patient trials or research, including malignant diseases, autoimmune diseases, severe malnutrition, etc.; and diseases that seriously affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc. (6) Women during pregnancy and lactation.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cough index;
- Secondary Outcome Measures
Name Time Method cough disappear rate at the 7th day;time of cough diappear day;TCM symdrome efficacy;cough VAS score;cough relieve time;